Entering text into the input field will update the search result below

Neuralstem up 11% premarket on preclinical Alzheimer's data

Jun. 26, 2015 8:44 AM ETPalisade Bio, Inc. (PALI) StockBy: Douglas W. House, SA News Editor5 Comments
  • Micro cap Neuralstem (CUR) is up 11% premarket on light volume in apparent response to its announcement of a poster presentation at the International Society for Stem Cell Research Annual Meeting in Stockholm, Sweden.
  • The poster, "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease," (AD) was presented by researchers from the University of Michigan. Mice with an animal model of AD were transplanted with HK532-IGF-1 cells in the peri-hippocampus. They performed better on hippocampal-dependent behavioral tasks than untreated mice which demonstrated enhanced learning cognitive processes and memory consolidation. There was also a reduction in beta-amyloid plaques in both the cortex and hippocampus of the treated mice. Amyloid plaque is one of the two hallmarks of AD.
  • HK532-IGF-1, the company's second stem cell line, is a proprietary line of cortical neural stem cells engineered to express insulin-like growth factor-1, which has demonstrated wide-ranging neuroprotective properties. Its development is ongoing.

Recommended For You

About PALI Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PALI--
Palisade Bio, Inc.